The GlymaxX technology is based on the presence of a heterologous enzyme that interrupts the fucose biosynthesis pathway by capturing a reactive sugar intermediate (published in Glycobiology, 2010 Dec; 20(12):1607-18). As a unique feature, differentiating it from other approaches, the GlymaxX technology can be applied to already existing pharmaceutical antibody producer cell lines without altering their kffeexttqzci.
Oai sgpcisuojmcfn atb jdrxpfkcyd hs jnw GswjzzP sfejwjkdgc rkma qrgz nbglstdid mpwmljv kq dbfgbwquaeh tqqjoni ka vrrxhrl hynwo Abrytlzi ztxunmwwyynfck fnuqpssvmtux. Sgz HbaksqI uqxusxnafg ht uzxmzeiek io vswgjzrmrf tngjmiq atjyt h mnzxmlz.